Panacea Life Sciences Holdings Inc Revenue Growth Rates (EXDI), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Panacea Life Sciences Holdings Inc   (EXDI)
 

EXDI's Revenue Growth by Quarter and Year

Panacea Life Sciences Holdings Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EXDI Revenue (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 1.06
FY 1.06

EXDIs Annual Revenue
Panacea Life Sciences Holdings Inc 's Revenue in the fiscal year 2023 $ 2.12 millions
Panacea Life Sciences Holdings Inc 's Revenue in the fiscal year 2022 $ 1.63 millions
Panacea Life Sciences Holdings Inc 's Revenue in the fiscal year 2021 $ 2.06 millions
Panacea Life Sciences Holdings Inc 's Revenue in the fiscal year 2020 $ 2.07 millions
Panacea Life Sciences Holdings Inc 's Revenue in the fiscal year 2019 $ 0.35 millions




EXDI Revenue first quarter 2024 Y/Y Growth Comment
Panacea Life Sciences Holdings Inc reported Revenue rise of 55.36% year on year in the first quarter 2024, to $ 1.06 millions, this is lower than Panacea Life Sciences Holdings Inc 's recent average Revenue surge of 590.24%.

Looking into first quarter 2024 results within Legal Cannabis industry 4 other companies have achieved higher Revenue growth. While Panacea Life Sciences Holdings Inc ' s Revenue jump of 55.36% ranks overall at the positon no. 367 in the first quarter 2024.


EXDI Revenue ( Y/Y Growth %) 2024
 2023 2022 2021
4th Quarter December - 200 % -50.77 % 2066.67 %
3rd Quarter September - -5.41 % -37.29 % -55.97 %
2nd Quarter June - -14.89 % 51.61 % -94.97 %
1st Quarter March 55.36 % 44.68 % -7.84 % -39.29 %
FY   - 46.63 % -20.87 % -

Financial Statements
Panacea Life Sciences Holdings Inc 's first quarter 2024 Revenue $ 1.06 millions EXDI's Income Statement
Panacea Life Sciences Holdings Inc 's first quarter 2023 Revenue $ 0.68 millions Quarterly EXDI's Income Statement


EXDI Revenue (Quarter on Quarter Growth %)

 2024
 2023 2022 2021
4th Quarter December - 174.29 % -13.51 % 10.17 %
3rd Quarter September - -12.5 % -21.28 % 90.32 %
2nd Quarter June - -41.18 % 0 % -39.22 %
1st Quarter March 10.05 % 112.5 % -27.69 % 1600 %
FY (Year on Year)   - 46.63 % -20.87 % -


Back to EXDI Growth rate Comparisons >> Back to EXDI Growth rate Comparisons >>


Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #5
Consumer Non Cyclical Sector #22
Overall #367

Revenue Y/Y Growth Statistics
High Average Low
5131.54 % 590.24 % -100 %
(Dec 31 2020)   (Jun 30 2023)
Revenue first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry #5
Consumer Non Cyclical Sector #22
Overall #367
Revenue Y/Y Growth Statistics
High Average Low
5131.54 % 590.24 % -100 %
(Dec 31 2020)   (Jun 30 2023)

Revenue by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Panacea Life Sciences Holdings Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
774.11 % 77.4 % -100 %
(Jun 30 2019)  


EXDI's I. Quarter Q/Q Revenue Comment
Panacea Life Sciences Holdings Inc achieved in the I. Quarter 2024 below company average Revenue rise of 10.05% quarter on quarter, to $ 1.06 millions.

Within Legal Cannabis industry only one company achieved higher sequential Revenue growth. While Panacea Life Sciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 216.


Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #2
Consumer Non Cyclical Sector #14
Overall #216
Revenue Q/Q Growth Company Ranking
Within: No.
Legal Cannabis Industry #2
Consumer Non Cyclical Sector #14
Overall #216
Revenue Q/Q Growth Statistics
High Average Low
774.11 % 77.4 % -100 %
(Jun 30 2019)  


EXDI's I. Quarter Q/Q Revenue Comment
Panacea Life Sciences Holdings Inc achieved in the I. Quarter 2024 below company average Revenue rise of 10.05% quarter on quarter, to $ 1.06 millions.

Within Legal Cannabis industry only one company achieved higher sequential Revenue growth. While Panacea Life Sciences Holdings Inc 's Revenue growth quarter on quarter, overall rank is 216.


Panacea Life Sciences Holdings Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Dec 31 2023)		 12 Months Ending
(Sep 30 2023)		 12 Months Ending
(Jun 30 2023)		 12 Months Ending
(Mar 31 2023)
Cumulative Revenue 12 Months Ending $ 2.76 $ 2.38 $ 1.75 $ 1.77 $ 1.84
Y / Y Revenue Growth (TTM) 50.38 % 46.59 % -10.21 % -18.54 % -8.74 %
Year on Year Revenue Growth Overall Ranking # 3338 # 0 # 3012 # 2936 # 3339
Seqeuential Revenue Change (TTM) 15.89 % 36.34 % -1.04 % -3.83 % 12.97 %
Seq. Revenue Growth (TTM) Overall Ranking # 953 # 0 # 2743 # 1765 # 1428


Cumulative Revenue growth Comment
Although Panacea Life Sciences Holdings Inc 's Annual Revenue growth year on year were below company's average 79.23% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 50.38% year on year, from 46.59% in Dec 31 2023.

In the Consumer Non Cyclical sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3338.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 6
Consumer Non Cyclical Sector # 138
Overall # 3338

Revenue TTM Y/Y Growth Statistics
High Average Low
499.11 %
 79.23 %
-34.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 29
S&P 500 # 953
Cumulative Revenue growth Comment
Although Panacea Life Sciences Holdings Inc 's Annual Revenue growth year on year were below company's average 79.23% , Revenue announced in the Mar 31 2024 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 50.38% year on year, from 46.59% in Dec 31 2023.

In the Consumer Non Cyclical sector 137 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 0 to 3338.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Legal Cannabis Industry # 6
Consumer Non Cyclical Sector # 138
Overall # 3338

Revenue TTM Y/Y Growth Statistics
High Average Low
499.11 %
79.23 %
-34.09 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 6
Sector # 29
S&P 500 # 953




Other Revenue Growth
Legal Cannabis Industry Revenue Growth Trends and Statistics
Consumer Non Cyclical Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
EXDI's Revenue Growth Ratio versus Legal Cannabis Industry, Consumer Non Cyclical Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Mar 31 2024 within Consumer Non Cyclical SectorY/Y Change %Revenue for the quarter ending Mar 31 2024
China Foods Holdings Ltd 95.54%$ 95.543 millions
Healthier Choices Management Corp 89.79%$ 89.787 millions
Senestech Inc 78.11%$ 78.112 millions
Dswiss Inc 77.26%$ 77.262 millions
Shineco Inc 71.95%$ 71.950 millions
Intelligent Hotel Group Ltd.57.29%$ 57.291 millions
Panacea Life Sciences Holdings Inc 55.94%$ 55.938 millions
Naturalshrimp Incorporated53.98%$ 53.978 millions
Cronos Group Inc 53.44%$ 53.438 millions
Fitlife Brands Inc 51.68%$ 51.676 millions
Legend Spices Inc 50.00%$ 50.000 millions
Cyanotech Corp42.36%$ 42.359 millions
Celsius Holdings Inc 36.65%$ 36.650 millions
Freshpet Inc 33.21%$ 33.211 millions
Nocera Inc 33.09%$ 33.086 millions
Jones Soda Co 29.17%$ 29.173 millions
Bellring Brands Inc 28.27%$ 28.268 millions


About Panacea Life Sciences Holdings Inc Revenue Growth Rates (EXDI), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Panacea Life Sciences Holdings Inc (CIK 1552189).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001493152-24-017858
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Panacea Life Sciences Holdings Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.